Cytosorbents shares
WebMar 10, 2024 · Cytosorbents Corp's market capitalization is $163.85 M by 43.64 M shares outstanding. Is Cytosorbents stock a Buy, Sell or Hold? Cytosorbents stock has … WebApr 13, 2024 · Cytosorbents is a smaller company with a market capitalization of US$389m, so it may still be flying under the radar of many institutional investors. Taking a look at our data on the ownership...
Cytosorbents shares
Did you know?
WebCytoSorbents aims to be in the elite company of fast growing medical device companies, with rapid growth, industry leading product gross margins in excess of 80%, and GAAP … WebApr 12, 2024 · Cytosorbents issued an update on its fourth quarter 2024 earnings guidance on Tuesday, January, 31st. The company provided earnings per share guidance of for …
WebMar 28, 2024 · Cytosorbents Co. ( NASDAQ:CTSO – Get Rating) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.13 and traded as high as $3.38.... WebWarrants: 50% Warrant coverage as follows: The Company will issue the Creditor five-year warrants (the “Warrants”) to purchase that number of shares of Common Stock equal to the quotient obtained by dividing (x) 50% of the Principal, by (y) $0.10, with the resulting number of shares having an exercise price equal to $0.125 per share of Common Stock.
WebApr 12, 2024 · See the latest CytoSorbents Corp stock price (NASDAQ:CTSO), related news, valuation, dividends and more to help you make your investing decisions. WebJan 18, 2024 · CytoSorbents Issues Shareholder Letter from CEO and Reports Preliminary Fourth Quarter and Full Year 2024 Revenue The Company expects to report fully-audited financial results for Q4 2024 and...
WebFeb 15, 2024 · Cytosorbents Corporation Common Stock (CTSO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Skip to main …
Web1 of 3 CTSO vs Medical Device Stocks View Top Medical Device Stocks Cytosorbents Stock Ownership FAQ Who owns Cytosorbents? Cytosorbents ( NASDAQ: CTSO) is owned by 33.56% institutional shareholders, 60.30% Cytosorbents 6.14% therapielanfWebJan 26, 2024 · Cytosorbents is a smaller company with a market capitalization of US$415m, so it may still be flying under the radar of many institutional investors. In the chart below, we can see that... therapie landeckWebApr 11, 2024 · Shares of Cytosorbents Co. (NASDAQ:CTSO – Get Rating) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.24 and traded as high as $3.33. therapielaser behounekWebCytoSorb ® is a unique blood purification therapy to control deadly inflammation in life-threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed … therapie lemgoWebSep 30, 2013 · The shares of Common Stock deliverable upon such exercise, and as adjusted from time to time, are hereinafter sometimes referred to as “Warrant Shares” and the corresponding exercise price of a share of Common Stock in effect at any time and as adjusted from time to time is hereinafter sometimes referred to as the “Exercise Price.” therapie laryngitisWebApr 12, 2024 · Of the 39 institutional investors that sold Cytosorbents stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Redmile Group LLC ($1.15M), Sectoral Asset Management Inc ($0.83M), State Street Corp ($0.57M), Goldman Sachs Group Inc. ($0.45M), Northern Trust Corp ($0.36M), … therapielampen winterdepressionWebApr 5, 2024 · Short selling CTSO is an investing strategy that aims to generate trading profit from Cytosorbents as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. signs of post-traumatic stress disorder